median survival 中文意思是什麼
median survival
解釋
生存中值-
On the other hand, there is substanial evidences tha dcs mediate tolerane. the gm - csf - stbolated mouse bone mwderived mhc class ii + dc progendors tha are deficient in cell surface erpression of the costbolatory molecules b7 - l and b7 - 2 can induce alloanginspecific t ceil anergy in vbo. systendc adchstraion of these donor - derived dc progendors to recipients intravenously 7 days before transplantation prolonged the median graft survival tane from 9. 5 days to 22 days wbout additional twnosuppressions in a mouse cardinc twlanation model
1995年， lul等報道表面缺乏共刺激分子，特別是缺乏cd80 （ b7 - 1 ）和cd86 （ b7 - 2 ）的未成熟型dc能在體外誘導同種抗原特異性的t細胞無能，而對dc的適當處理能夠使未成熟型dc潛在的耐受原性得以放大和增強，使得dc在誘導免疫耐受中具有相當重要的作用及潛在的應用價值。 -
The median overall survival time for patients in the avastin plus carboplatin and paclitaxel arm was 12. 3 months versus 10. 3 months for patients receiving only carboplatin and paclitaxel
阿瓦斯丁聯合卡鉑和紫杉醇的平均生存時間為12 . 3個月，與之相對的單用卡鉑和紫杉醇的為10 . 3個月。 -
Results : the median survival was 11 months, with a 3 - year survival of 24 %
結果：平均生存時間是11個月， 3年生存率為24 。 -
For men, median post - transplant survival was 18 years, compared with 27 for the general population
女性的均肝移植有成活率是26年，對照普通大眾為31年。 -
Survival was significantly worse for patients with n2 disease than for those with no lymph node metastasis ( median survival 10 months vs 29 months, respectively, p =. 005 )
值得注意的是n2期的生存率要比沒有淋巴結轉移的病人要更差（平均生存時間分別為10個月和29個月， p . 005 ） 。 -
It has been shown in randomized studies that chemotherapy prolongs the median survival and improves the quality of life of patients with advanced gastric cancer compared to best supportive care, so a chemotherapeutic treatment should be proposed to the patient
隨機研究顯示出化療較最佳支持治療可以延長晚期胃癌患者的中位生存並改善患者的生活質量。 -
Methods by defining defaulting as a failure event and time from treatment starting to defaulting as survival time, we applied survival analysis technique with a real data to estimate a so called adherent rate and a median adherent time for evaluation of treatment adherence for patients with tuberculosis
方法將退出療程作為所關心的結局事件，將從登記治療開始到退出療程的時間作為堅持治療時間，利用生存分析統計技術估計堅持治療率和中位堅持治療時間以評價結核病患者的治療依從性。 -
The median survival time for the entire sample was 34 months
二年及五年的存活率各為65 %及25 % 。
分享友人